Head to Head Contrast: Klotho Neurosciences (NASDAQ:KLTO) vs. Kymera Therapeutics (NASDAQ:KYMR)

Kymera Therapeutics (NASDAQ:KYMR) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

20.1% of Klotho Neurosciences shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 26.7% of Klotho Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Kymera Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of -1.1, meaning that its stock price is 210% less volatile than the S&P 500.

Earnings and Valuation

This table compares Kymera Therapeutics and Klotho Neurosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$58.89 million	33.40	-$146.96 million	($3.10)	-9.74
Klotho Neurosciences	N/A	N/A	$1.35 million	($0.36)	-0.64

Klotho Neurosciences has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Klotho Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kymera Therapeutics and Klotho Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-191.26%	-24.96%	-20.27%
Klotho Neurosciences	N/A	N/A	-25.89%

Analyst Ratings

This is a breakdown of recent ratings for Kymera Therapeutics and Klotho Neurosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0	4	11	1	2.81
Klotho Neurosciences	0	0	0	0	0.00

Kymera Therapeutics presently has a consensus price target of $55.27, indicating a potential upside of 83.00%. Given Kymera Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Kymera Therapeutics is more favorable than Klotho Neurosciences.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.